BioStock: FDA approval and strong data position Alzinova ahead of Phase II
Alzinova’s Q3 report, published today, places strong emphasis on the ongoing preparations for the planned Phase II study with the vaccine candidate ALZ-101. Backed by both FDA approval and Fast Track designation, the company is now gearing up for its next stage of development. Up next is the presentation of research data at CTAD in December, further strengthening the case for ALZ-XNUMX’s potential as a disease-modifying treatment for Alzheimer’s disease. BioStock spoke with CEO Tord Labuda for a comment.
Read the full interview at biostock.se:
FDA approval and strong data position Alzinova for Phase II
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/